Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Drug Metabolism > Retatrutide for Sale > High Purity Retatrutide Powder weight loss CAS 2381089-83-2 | 99.9% Weight Management Peptide
High Purity Retatrutide Powder weight loss CAS 2381089-83-2 | 99.9% Weight Management Peptide buy - large image1
High Purity Retatrutide Powder weight loss CAS 2381089-83-2 | 99.9% Weight Management Peptide buy - image1
High Purity Retatrutide Powder weight loss CAS 2381089-83-2 | 99.9% Weight Management Peptide buy - image2
High Purity Retatrutide Powder weight loss CAS 2381089-83-2 | 99.9% Weight Management Peptide buy - image3

High Purity Retatrutide Powder weight loss CAS 2381089-83-2 | 99.9% Weight Management Peptide

7503 Inquiries

Unit Price:

$10-12/UNIT FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shanghai

Packaging:

5mg/vial,10mg/vial,15mg/vial

Sample Available:

Yes

Price valid (until):

2027-03-03

The product will be displayed normally on the website later.
Company Type:
Distributor
Location:
China
Average Lead Time:
1 days
Qualification:
Main Products:

GLP-1,Retatrutide,Selank,Tirzepatide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  

    Name:Elsie

    WeChat and WhatsApp: +8 5294406371

    Email:Elsie@weishanen.cn



    Retatrutide (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

    Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively.

    In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.

    Retatrutide, LY3437943

    CAS#: 2381089-83-2

    Molecular Formula: C221H342N46O68

    Molecular Weight: 4731.33

    Sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

    Appearance: White Powder

    Purity (HPLC): ≥99.0%

    Single Impurity (HPLC): ≤1.0%

    Sodium Content (HPLC): 5.0%-12.0%

    Moisture Content (Karl Fischer): ≤10.0%

    Peptide Content: ≥80.0%

    Storage: Store at 2-8 degrees Celsius in a dry and cool place.

    Packaging: 1g-1kg, plastic bottle

    Intended Use: For scientific research purposes

    t...

    Items Specifications






    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Drug Metabolism

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Distributor

    Main Products:

    GLP-1,Retatrutide,Selank,Tirzepatide

    Location:

    Room 704#-A010, Building 11, Block 16, Liangzhu Street, Yuhang District, Hangzhou City, Zhejiang Province

    Average lead Time:

    1 days

    Total Annual Revenue:

    Less than $1 million

    Total Employees:

    11-50

    Year of Establishment:

    2025

  • Inquiry History
    7503 Inquiries
    Country Product Purchase Quantity Date Posted
    Malaysia

    Retatrutide

    20 MG Oct 28, 2026
    Australia

    Retaturtide

    100 MG Oct 29, 2026
    United States

    Retatrutide 30mg and 50mg

    20 PCS Oct 29, 2026
    Belgium

    Retatrutide

    1 MG Oct 29, 2026
    Romania

    Retatrutide

    10 G Oct 29, 2026
    United States

    Retatrutide

    2 MT Oct 29, 2026
    United States

    Retatrutide

    1 MT Oct 29, 2026
    United Kingdom

    Retatrutide

    1 PCS Oct 28, 2026
    United States

    Retatrutide

    30 MT Oct 28, 2026
    United Kingdom

    Retatrutide

    10 MT Oct 28, 2026
    United States

    retatrutide

    30 MG Oct 28, 2026
    Czech

    Retatrutide

    10 MG Oct 28, 2026
    Austria

    retatrutide

    30 MG Oct 28, 2026
    United States

    Retatrutide

    100 KG Oct 28, 2026
    Malta

    Retatrutide

    10 MT Oct 28, 2026
    United States

    Retatrutide

    600 MG Oct 28, 2026
    United States

    Retatrutide

    500 G Oct 28, 2026
    United States

    Retatrutide

    60 G Oct 28, 2026
    Croatia

    Retatrutide

    10 MG Oct 28, 2026
    United States

    Retatrutide

    200 MG Oct 28, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.